318 results on '"Wu, Shenhong"'
Search Results
2. Cabozantinib tolerability in metastatic renal cell carcinoma: A meta-analysis.
3. Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis
4. Risks and management of hypertension in cancer patients undergoing targeted therapy: a review
5. Emerging therapeutic agents for genitourinary cancers
6. Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis
7. Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma
8. Risk of Rash Associated With Lenalidomide in Cancer Patients: A Systematic Review of the Literature and Meta-analysis
9. The Utility of 24-h Ambulatory Blood Pressure Monitoring for the Diagnosis and Management of White Coat Hypertension in a Primary Care Setting
10. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis
11. Inverse association between eczema and meningioma: a meta-analysis
12. Reply to: “Skin moisturization for xerosis related to targeted anticancer therapies”
13. Incidence and risk of xerosis with targeted anticancer therapies
14. Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non–Renal Cell Carcinoma: A Meta-analysis
15. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
16. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis
17. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis
18. Improving tolerability of pembrolizumab with weight based dosing: A meta-analysis.
19. Tolerability of axitinib in advanced renal cell carcinoma: A meta-analysis.
20. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis
21. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis
22. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
23. Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis
24. Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis
25. The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
26. Incidence of alopecia from endocrine therapies in cancer: P6446
27. Risk of pruritus in cancer patients treated with cetuximab: A systematic review of the literature and metaanalysis: P6967
28. Risk of pruritus in cancer patients treated with inhibitors of the mammalian target of rapamycin, everolimus and temsirolimus: A systematic review of the literature and metaanalysis: P7000
29. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4
30. Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization
31. The efficacy of temozolomide for recurrent glioblastoma multiforme
32. The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis
33. Risk of Rash in Cancer Patients Treated with Vandetanib: Systematic Review and Meta-Analysis
34. Bevacizumab and Cancer Treatment-Related Mortality—Reply
35. Treatment-Related Mortality With Bevacizumab in Cancer Patients: A Meta-analysis
36. Risk of hypocalcemia in cancer patients treated with cabozantinib: A meta-analysis.
37. Tolerability of enzalutamide in prostate cancer: A meta-analysis.
38. Tolerability of dual checkpoint blockade with nivolumab and ipilimumab: A meta-analysis.
39. Tolerability of single agent nivolumab in cancer patients—A meta-analysis.
40. Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis
41. Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
42. Incidence and risk of developing photosensitivity with targeted anticancer therapies
43. Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis
44. Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients
45. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy
46. Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-analysis
47. Persistent Hypocalcemia Induced by Zoledronic Acid in a Patient with Androgen-Independent Prostate Cancer and Extensive Bone Metastases
48. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer
49. Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone
50. The Kinetic Stability of MHC Class II:Peptide Complexes Is a Key Parameter that Dictates Immunodominance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.